FDA Aligns with Gemini Therapeutics on APOLLO Trial Design for Bitopertin in Rare Porphyria Disorders
Key Insights
Gemini Therapeutics (search) has successfully concluded a Type C meeting with the FDA, reaching agreement on the design of APOLLO (search) confirmatory trial for bitopertin in EPP and XLP treatment.
The planned APOLLO (search) trial will enroll approximately 150 patients across multiple continents in a randomized, double-blind, placebo-controlled study with a 1:1 allocation ratio.
The company aims to submit a New Drug Application for bitopertin under the Accelerated Approval Program in the second half of 2025, with trial initiation planned for mid-2025.
Gemini Therapeutics (search) has achieved a significant milestone in its development program for bitopertin, securing alignment with the U.S. Food and Drug Administration (FDA) on the design of its post-marketing confirmatory trial, APOLLO (search), for treating Erythropoietic Protoporphyria (search) (EPP) and X-linked Protoporphyria (search) (XLP).
Trial Design and Scope
The APOLLO (search) trial has been structured as a comprehensive global study, incorporating key elements agreed upon during the Type C meeting with the FDA. The trial will feature a robust design, including:
- Approximately 150 patient enrollment
- 1:1 randomization ratio
- Double-blind, placebo-controlled methodology
- Clearly defined co-primary endpoints
- Specific patient inclusion criteria
- Predetermined dosage selection parameters
Global Implementation Strategy
The company has outlined an ambitious geographical reach for the APOLLO (search) trial, with planned study sites across multiple regions:
- United States
- Canada
- Europe
- Australia
This multi-regional approach aims to ensure diverse patient representation and broader applicability of results.
Regulatory Pathway and Timeline
Gemini Therapeutics (search) has established a clear regulatory timeline for bitopertin's development:
- Trial initiation targeted for mid-2025
- New Drug Application (NDA) submission planned for second half of 2025
- Pursuit of approval through FDA's Accelerated Approval Program
The accelerated approval pathway reflects the urgent need for effective treatments for EPP and XLP, rare genetic disorders that currently have limited therapeutic options.
Clinical Impact and Market Significance
The advancement of bitopertin through this regulatory milestone represents a potentially significant development for patients suffering from EPP and XLP. These rare genetic disorders, characterized by severe photosensitivity (search) and acute painful photoreactions (search), currently lack comprehensive treatment options.
The company's strategic approach, combining rigorous trial design with an accelerated regulatory pathway, demonstrates its commitment to addressing unmet medical needs in the rare disease space. This development also positions Gemini Therapeutics (search) as a key player in the advancement of treatments for hematologic disorders.
Corporate Strategy
Gemini Therapeutics (search), previously known as Disc Medicine, Inc., continues to strengthen its position in the development of novel therapeutics for hematologic disorders. The successful Type C meeting outcome reflects the company's effective engagement with regulatory authorities and its strategic focus on bringing innovative treatments to market.